Risk of repeat heart attack twice as likely from occlusions in arteries that did not cause initial event
Pressmeddelanden • Jan 16, 2018 16:42 CET
AstraZeneca announced today the publication of a new analysis from an ongoing real-world quality registry that suggests the risk of experiencing a repeat heart attack (also known as a myocardial infarction or MI) from occlusions in non-stentedarteries is twice as high as the risk stemming from the initially stented artery following a first heart attack.
Pressmeddelanden • Jan 12, 2018 17:20 CET
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),
Pressmeddelanden • Jan 10, 2018 16:28 CET
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.
US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
Pressmeddelanden • Dec 18, 2017 08:03 CET
AstraZeneca to highlight its commitment to blood cancers at the 2017 American Society of Hematology Annual Meeting
Pressmeddelanden • Dec 06, 2017 08:02 CET
AstraZeneca, along with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in blood cancer research at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA
Pressmeddelanden • Dec 04, 2017 08:04 CET
AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
The European Medicines Agency accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
Pressmeddelanden • Nov 28, 2017 08:15 CET
AstraZeneca today announced that the European Medicines Agency has accepted a variation to the Marketing Authorisation Application (MAAv) for Tagrisso (osimertinib),
AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China
Pressmeddelanden • Nov 27, 2017 08:17 CET
AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to discover, develop and commercialise potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster.
AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan
Pressmeddelanden • Nov 27, 2017 08:04 CET
AstraZeneca today announced the submission of a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency for the use of Tagrisso (osimertinib).
Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
Pressmeddelanden • Nov 15, 2017 08:03 CET
Pressmeddelanden • Nov 15, 2017 08:01 CET
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Pressmeddelanden • Nov 10, 2017 13:05 CET
Pressmeddelanden • Nov 09, 2017 08:39 CET
AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017
Pressmeddelanden • Nov 08, 2017 08:02 CET
AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.
Pressmeddelanden • Nov 01, 2017 08:06 CET
FDA godkänner AstraZenecas Calquence (acalabrutinib) för vuxna patienter med tidigare behandlad mantelcellslymfom
Pressmeddelanden • Okt 31, 2017 18:23 CET
AstraZeneca och dess FoU-center för hematologi, Acerta Pharma, meddelar idag att den amerikanska läkemedelsmyndigheten FDA har godkänt Calquence(acalabrutinib) inom ramen för så kallat ”påskyndat godkännande” Calquence är en tyrosinkinashämmare och indikationen gäller behandling av vuxna patienter med mantelcellslymfom (MCL) som har fått minst en tidigare behandling. 1
Pressmeddelanden • Okt 31, 2017 08:14 CET
AstraZeneca and MedImmune, its global biologics research and development arm, today announced the expansion of their clinical collaboration with Incyte Corporation.
Pressmeddelanden • Okt 23, 2017 08:14 CEST
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US today announced that they have submitted a new drug application (NDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Lynparza(olaparib) tablets in unresectable or recurrent BRCA-mutated breast cancer, with a decision expected in the second half of 2018.
US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes
Pressmeddelanden • Okt 23, 2017 08:06 CEST
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of Bydureon in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise
US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants priority review
Pressmeddelanden • Okt 18, 2017 08:03 CEST
Lynparza has the potential to offer a new treatment option for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer Regulatory submission acceptance is first for a PARP inhibitor beyond ovarian cancer